Experimental agent briefly eases depression rapidly in test: Works in brain like ketamine, with fewer side effects

December 11, 2012

(Medical Xpress)—A drug that works through the same brain mechanism as the fast-acting antidepressant ketamine briefly improved treatment-resistant patients' depression symptoms in minutes, with minimal untoward side effects, in a clinical trial conducted by the National Institutes of Health. The experimental agent, called AZD6765, acts through the brain's glutamate chemical messenger system.

Existing antidepressants available through prescription, which work through the brain's serotonin system, take a few weeks to work, imperiling severely depressed patients, who can be at high risk for suicide. Ketamine also works in hours, but its usefulness is limited by its potential for dissociative side-effects, including hallucinations. It is being studied mostly for clues to how it works.

"Our findings serve as a that we can tap into an important component of the pathway to develop a new generation of safe, rapid-acting practical treatments for depression," said Carlos Zarate, M.D., of the NIH's National Institute of Mental Health, which conducted the research.

Zarate, and colleagues, reported on their results online Dec. 1, 2012 in the journal Biological Psychiatry.

AZD6765, like ketamine, works by blocking glutamate binding to a protein on the surface of neurons, called the . It is a less powerful blocker of the NMDA receptor, which may be a reason why it is better tolerated than ketamine.

About 32 percent of 22 treatment-resistant infused with ASD6765 showed a clinically meaningful antidepressant response at 80 minutes after infusion that lasted for about half an hour—with residual antidepressant effects lasting two days for some. By contrast, 52 percent of patients receiving ketamine show a comparable response, with effects still detectable at seven days. So a single infusion of ketamine produces more robust and sustained improvement, but most patients continue to experience some symptoms with both drugs.

However, depression rating scores were significantly better among patients who received AZD6765 than in those who received placebos. The researchers deemed this noteworthy, since, on average, these patients had failed to improve in seven past antidepressant trials, and nearly half failed to respond to electroconvulsive therapy (ECT).

The patients reported only minor side effects, such as dizziness and nausea, which were not significantly different from those experienced with the placebo.

Zarate and colleagues say their results warrant further trials with AZD6765, testing whether repeated infusions a few times per week or higher doses might produce longer-lasting results.

Explore further: Ketamine improved bipolar depression within minutes

More information: Zarate, C. et al., A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression, Biol Psychiatry. 2012 Nov 30. doi:pii: S0006-3223(12)00941-9. 10.1016/j.biopsych.2012.10.019

Related Stories

Ketamine improved bipolar depression within minutes

May 30, 2012
Bipolar disorder is a serious and debilitating condition where individuals experience severe swings in mood between mania and depression. The episodes of low or elevated mood can last days or months, and the risk of suicide ...

'Special K' could relieve depression

June 7, 2012
(Medical Xpress) -- Recreational drug and anaesthetic, ketamine, is being trialled in people with severe depression and is providing almost instant relief from symptoms, offering fresh hope of a quick new way to manage the ...

Ketamine helps see how the brain works in clinical depression

June 16, 2011
(Medical Xpress) -- In a new study published in Nature, Lisa Monteggia from the University of Texas Southwestern Medical Center looks at how the drug ketamine, typically used as an anesthetic or a popular recreational drug ...

Recommended for you

Exposure to violence hinders short-term memory, cognitive control

July 24, 2017
Being exposed to and actively remembering violent episodes—even those that happened up to a decade before—hinders short-term memory and cognitive control, according to a study published in the Proceedings of the National ...

Using money to buy time linked to increased happiness

July 24, 2017
New research is challenging the age-old adage that money can't buy happiness.

Researchers pave new path toward preventing obesity

July 24, 2017
People who experience unpredictable childhoods due to issues such as divorce, crime or frequent moves face a higher risk of becoming obese as adults, according to a new study by a Florida State University researcher.

Higher cognitive abilities linked to greater risk of stereotyping

July 24, 2017
People with higher cognitive abilities are more likely to learn and apply social stereotypes, finds a new study. The results, stemming from a series of experiments, show that those with higher cognitive abilities also more ...

Psychologists say our 'attachment style' applies to social networks like Facebook

July 24, 2017
A new investigation appearing this week in the Personality and Social Psychology Bulletin suggests a strong association between a person's attachment style—how avoidant or anxious people are in their close relationships—and ...

World-first ketamine trial shows promise for geriatric depression

July 24, 2017
Australian researchers have completed the world's first randomised control trial (RCT) assessing the efficacy and safety of ketamine as a treatment for depression in elderly patients.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.